ATE110265T1 - Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums. - Google Patents

Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.

Info

Publication number
ATE110265T1
ATE110265T1 AT90908385T AT90908385T ATE110265T1 AT E110265 T1 ATE110265 T1 AT E110265T1 AT 90908385 T AT90908385 T AT 90908385T AT 90908385 T AT90908385 T AT 90908385T AT E110265 T1 ATE110265 T1 AT E110265T1
Authority
AT
Austria
Prior art keywords
anxiolytic
manufacture
sigma receptor
receptor ligands
sigma
Prior art date
Application number
AT90908385T
Other languages
English (en)
Inventor
John F W Keana
Eckard Weber
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Application granted granted Critical
Publication of ATE110265T1 publication Critical patent/ATE110265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT90908385T 1989-05-02 1990-05-02 Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums. ATE110265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34649489A 1989-05-02 1989-05-02

Publications (1)

Publication Number Publication Date
ATE110265T1 true ATE110265T1 (de) 1994-09-15

Family

ID=23359655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908385T ATE110265T1 (de) 1989-05-02 1990-05-02 Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.

Country Status (9)

Country Link
EP (1) EP0473671B1 (de)
JP (1) JPH05500798A (de)
AT (1) ATE110265T1 (de)
AU (1) AU642881B2 (de)
CA (1) CA2054211A1 (de)
DE (1) DE69011859T2 (de)
DK (1) DK0473671T3 (de)
ES (1) ES2057568T3 (de)
WO (1) WO1990014067A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312840A (en) * 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5385946A (en) * 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
DE69133065T2 (de) 1990-03-02 2003-02-27 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Sciences University, Portland Tri- und tetra-substituierte guanidine und deren verwendung als antagonisten von exzitatorischen aminosäuren
WO1991018868A1 (en) * 1990-05-25 1991-12-12 STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY Substituted guanidines having high binding to the sigma receptor and the use thereof
DE69233479T2 (de) * 1991-02-08 2006-03-16 Scion Pharmaceuticals, Inc., Medford Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
US5741661A (en) * 1991-02-08 1998-04-21 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
ES2204920T3 (es) * 1993-05-27 2004-05-01 Cenes Limited Guanidinas substituidas terapeuticas.
JPH09505600A (ja) * 1993-11-22 1997-06-03 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 治療用グアニジン類
AU705487B2 (en) * 1993-11-23 1999-05-20 Cambridge Neuroscience, Inc. Therapeutic substituted guanidines
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
WO1995020950A1 (en) 1994-02-03 1995-08-10 Cambridge Neuroscience, Inc. Therapeutic guanidines
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
WO1995023132A1 (en) * 1994-02-23 1995-08-31 Cambridge Neuroscience, Inc. Blockers of ion channels and methods of use thereof
US6756389B2 (en) 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1749824A1 (de) 2005-08-03 2007-02-07 Neuro3D Benzodiazepinederivate, Herstellung und Verwendung als Arzneimittel
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9388126B2 (en) * 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use

Also Published As

Publication number Publication date
AU642881B2 (en) 1993-11-04
DE69011859T2 (de) 1994-12-15
JPH05500798A (ja) 1993-02-18
EP0473671A4 (en) 1992-04-01
EP0473671A1 (de) 1992-03-11
CA2054211A1 (en) 1990-11-03
WO1990014067A2 (en) 1990-11-29
ES2057568T3 (es) 1994-10-16
AU5728790A (en) 1990-12-18
DK0473671T3 (da) 1994-09-19
EP0473671B1 (de) 1994-08-24
DE69011859D1 (de) 1994-09-29
WO1990014067A3 (en) 1991-04-04

Similar Documents

Publication Publication Date Title
DE69011859D1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE173401T1 (de) Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
FR2491334B1 (de)
ATE1241T1 (de) Verfahren zur herstellung von 4,5-perfluor-1,3-dioxolanen.
DE59003791D1 (de) Verfahren zur Herstellung von 1,3,3-Trimethyl-5-oxo-cyclohexan-carbonitril.
DE69006911D1 (de) Verfahren zur Herstellung von 3,4-Dichloranilin.
DE59100547D1 (de) Verfahren zur Herstellung von linearen Polyamiden.
DE68914221D1 (de) Verfahren zur Herstellung von alifatischen alpha-omega-Diaminen, neue Verbindungen und deren Verwendung für die Haarfärbung.
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE69103473D1 (de) Verfahren zur Herstellung von 1-Chlor-1,2,2-trifluorethylen oder von 1,2,2-trifluorethylen.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE3885818D1 (de) Trinatriumsalz des 2,4,6-Trimercapto-s-triazin-nonahydrats und Verfahren zur Herstellung.
DE59005898D1 (de) Dinatriumsalz des Trimercapto-s-triazin-hexahydrats, Verfahren zu seiner Herstellung und Verwendung.
DE69009394D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethyl-1-cyclohexanon.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69007637D1 (de) Verfahren zur Herstellung von 1,1,3,4,4,6-Hexamethyl-1,2,3,4-tetrahydronaphthalin.
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DE59103040D1 (de) Verfahren zur Herstellung von symmetrischen 2,2'-Methylen-bis-benztriazolylphenolen.
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
DE59104221D1 (de) Verfahren zur Herstellung von 2,3,5-Trimethyl-p-benzochinon.
DE68906700D1 (de) Verwendung eines polypeptids zur herstellung einer zusammensetzung zur behandlung von pankreatitis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee